Acute Ischemic Stroke, Atrial Fibrillation
Conditions
Brief summary
Investigator-initiated prospective multicentre hospital-based registry to uncover the proportion of self-reported anticoagulation in stroke patients with atrial fibrillation and assessing the proportion of stroke, intracranial bleeding and all-cause death in the short (at 3 months), mid-term (at 12 months) as well as long term (at 24 months) after ischemic stroke or transient ischemic attack in an unselected urban population in Germany. In addition, annual follow-up is planned yearly up to 5 years after enrollment.
Interventions
None listed
Sponsors
Center for Stroke Research Berlin
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Charite University, Berlin, Germany
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Acute ischemic stroke or transient ischemic attack (with clinical deficit on admission or corresponding brain MRI lesion) * Age ≥ 18 years * Known atrial fibrillation or ECG recording documenting atrial fibrillation during the in-hospital stay for acute ischemic stroke or transient ischemic attack * Written or oral informed consent * Willingness to take part in the planned follow up examinations
Exclusion criteria
* Life expectancy \< 1 year (before stroke) * Assumed post-stroke life expectancy \< 1 month according to stroke severity * Chronic anticoagulation for reasons other than atrial fibrillation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient self-reported persistence to oral anticoagulants (novel oral anticoagulants or vitamin K antagonists) in stroke patients with AF at 12 months after ischemic stroke or TIA | 12 months |
Countries
Germany
Outcome results
None listed